This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
CNN’s David Gergen to keynote bioMérieux Scientific Symposium: Healthcare Reform: The Only Certainty is Change
Durham, NC (PRWEB) June 18, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, will demonstrate “The Microbiology Pathway: From Collection to Care” at the American Society for Microbiology (ASM) General Meeting in San Francisco. Attendees at ASM2012 will experience the Microbiology Pathway during guided lab tours showcasing the newest advancements in microbiology solutions and services at bioMérieux booth #1301.
The Microbiology Pathway depicts bioMérieux’s complete approach to improving efficiencies and patient care through optimized workflow and full microbiology lab automation. The Pathway workflow represents best practices to improve sample to result and deliver clinically relevant information as quickly as possible. The microbiology lab, which was once considered very difficult to automate, can be streamlined utilizing new breakthrough solutions for faster recovery times and identification, scientific developments and informatics.
bioMérieux, the world leader in microbiology, will also host its annual Scientific Symposium: “Healthcare Reform – The Only Certainty is Change.” Symposium speakers will address the inevitable changes facing the U.S. healthcare system and how hospitals can best prepare to adapt and continue to provide excellent care. Regardless of the Supreme Court ruling on the Patient Protection and Affordable Care Act (PPACA), the key drivers that motivated that law – the growing cost of care, uninsured patients, the need for modernized information technology, and medical errors – still must be addressed.
“We know from experience that optimized processes that streamline the pathway from specimen to result can dramatically improve patient care,” said Manuel O. Méndez, Executive Vice President and General Manager, bioMérieux Americas. “bioMérieux is sponsoring this Symposium to bring together policy members, hospital CEOs, clinicians and lab scientists, with the goal of starting a conversation with all stakeholders and demonstrating that what has worked in the lab, can be applied to the entire system. These changes can reduce costs, avert waste and save lives.”
The Scientific Symposium keynote address will be given by David Gergen, CNN’s senior political analyst and a previous adviser to four U.S. presidents. He is a professor of public service and director of the Center for Public Leadership at Harvard University’s Kennedy School of Government. Mr. Gergen is a close observer of healthcare reforms and their impact on American politics. In a recent interview with Modern Healthcare, Gergen said that the U.S. healthcare industry finds itself in a period of “extreme uncertainty and volatility,” explaining that recent reforms will persist despite the outcomes of upcoming elections.
Following the keynote address will be two presentations by Dr. Imran Andrabi, Senior Vice President and Chief Physician Executive Officer at Mercy Healthcare, and Dr. Geraldine Hall, Medical Director in Clinical Microbiology, Cleveland Clinic and Professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Andrabi’s presentation is titled: “Patients First, Journey to Zero. Creating an Outcome-based Culture,” which centers on the creation of an outcomes-based initiative to reduce waste, waiting times to see a doctor and medical errors at Mercy Healthcare. As a result of this effort, Dr. Andrabi has been nominated for the Excellence in Medical Education award twice. He has received various Who’s Who awards in medicine and healthcare, science and engineering, finance and industry. He is also a practicing physician.
Dr. Hall will deliver a presentation titled: “What are the Necessary Changes in Clinical Microbiology for 2012 and beyond?” Her talk will focus on the challenges facing the hospital lab due to an aging population, lower reimbursement rates and new technologies.
The bioMérieux Scientific Symposium will be held Monday, June 18 at the Yoshi Theater and Supper Club in San Francisco’s Fillmore District. The presentations begin at 6:00 p.m.
bioMérieux is also hosting its popular In-Booth Knowledge Forums at booth #1301. Topics include:
To learn more about these presentations and register for the Knowledge Forums or Scientific Symposium, please visit http://www.biomerieux-usa.com/asm2012.
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 40 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the NYSE Euronext Paris market.
Additional information can be found at http://www.bioMérieux-usa.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9617336.htm